Affiliation: Baylor College of Medicine
- Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trialBoadie W Dunlop
Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 12 Executive Park Drive NE, 3rd Floor, Atlanta, GA, USA
Trials 15:240. 2014..This Phase II trial aims to evaluate the efficacy of a CRH type 1 receptor (CRHR1) antagonist in the treatment of PTSD...
- Ketamine for treatment-resistant unipolar depression: current evidenceSanjay J Mathew
Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA
CNS Drugs 26:189-204. 2012..Given the potential risks of ketamine, safety considerations will ultimately determine whether this old drug is successfully repositioned as a new therapy for TRD...
- A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trialSanjay J Mathew
Mood and Anxiety Disorders Program, Department of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA
Eur Neuropsychopharmacol 21:221-9. 2011..The selective NK(1)R antagonist GR205171 had fewer adverse effects but was not significantly superior to placebo in the short-term treatment of chronic PTSD. (ClinicalTrials.gov Identifier: NCT 00211861, NCT 00383786)...
- Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trialKarl Rickels
Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA
J Clin Psychopharmacol 28:235-9. 2008..Collectively, these results support further clinical investigation of higher doses of PRX-00023 in anxiety and depression...